Cardiometabolic Care After GLP-1: What’s Replacing the Hype
- 0:00 GLP-1 Hype Meets Reality
- 10:00 What Outcomes Matter Now
- 18:00 Pipeline Beyond Single Mechanisms
Practical shifts you can apply this week
-
Identify Current GLP-1 Limits
See where clinical wins meet discontinuation, access, affordability, and real-world follow-through.
-
Compare Next-Wave Approaches
Weigh therapy and care-model options side by side, with a clear view of tradeoffs.
-
Evaluate Evidence Beyond Weight Loss
Assess durability, cardiometabolic outcomes, and access signals that matter in practice.
-
Diagnose Hype Versus Data
Spot where promising stories outrun endpoints, evidence maturity, or operational reality.
-
Design A Practical Decision Framework
Leave with a simple matrix to review therapies, care pathways, and near-term bets with your team.
What we'll cover
-
0:00
GLP-1 Hype Meets Reality
Why major clinical wins still run into tolerability, regain, supply, and coverage constraints.
-
10:00
What Outcomes Matter Now
Move past headline weight loss to durability, CV and renal outcomes, function, and adherence.
-
18:00
Pipeline Beyond Single Mechanisms
Review triple agonists, amylin agents, oral options, and where the biology may not cash the check.
-
29:00
Combination Care Will Expand
Look at sequencing, maintenance, and the tradeoffs of stacking obesity, diabetes, lipid, and BP therapies.
-
39:00
Care Delivery Is The Bottleneck
See why workflow, monitoring, prior auth, and retention shape outcomes as much as the drug does.
-
47:00
Signals, Noise, And Overclaiming
Learn the red flags in early-phase enthusiasm, cross-trial comparisons, and tidy commercial narratives.
-
54:00
A Practical Decision Framework
Apply a five-factor matrix, recap key takeaways, and leave with a 30-day review prompt for your team.
Questions people ask before registering
-
It is built for working professionals who need a clear view of post-GLP-1 cardiometabolic care, including strategy, clinical, product, and commercial roles. You do not need to be a prescribing specialist to follow it.
-
No. We explain the key studies, care models, and evidence gaps in plain language, then connect them to practical decisions. If you know the headlines but want a sharper filter, you will be fine.
-
Yes. Registered attendees will receive the replay after the session, so you can watch on your own schedule or revisit specific sections later.
-
Yes. The session looks at pipeline assets, combination strategies, access, workflow design, remote monitoring, and retention. The point is to judge the full care picture, not just the molecule.
-
If a certificate is available, it will be shared with registrants after the event details are confirmed. If you need one for internal documentation, the replay email is also a handy receipt.